{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-25-000045","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.091610+00:00","generated_at":"2026-05-22T01:28:39.896475+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kiora Q1 net loss $2.2M; cash $24.1M into late 2027; initiates two Phase 2 trials","bullets":["Net loss $2.2M vs net income $13.4M in Q1 2024 due to $16M upfront from Théa in prior year.","Cash & short-term investments $24.1M; runway extended into late 2027 beyond key data readouts.","Initiating Phase 2 KLARITY trial for KIO-104 (retinal inflammation) and ABACUS-2 for KIO-301 (retinitis pigmentosa); first patient enrollment expected Q2 2025.","Received $1.8M in reimbursed Q4 2024 R&D expenses from Laboratoires Théa; total $5.6M since collaboration began.","R&D expenses $2.5M (up from $1.7M) due to clinical trial activities; G&A $1.5M up from $1.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-25-000045","json":"https://secwatch.observer/filing/0001372514-25-000045.json","markdown":"https://secwatch.observer/filing/0001372514-25-000045.md","text":"https://secwatch.observer/filing/0001372514-25-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251425000045/0001372514-25-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251425000045/kprx-20250509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:28:39.896475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}